Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 21Leukemia, Myeloid, Acute 20Lymphoma, Non-Hodgkin 19Hodgkin Disease 18Multiple Myeloma 17Myelodysplastic Syndromes 16Lymphoma 16Graft vs Host Disease 16Lymphoma, Mantle-Cell 15Leukemia, Lymphocytic, Chronic, B-Cell 15Leukemia 14Sarcoma 11Lymphoma, Large B-Cell, Diffuse 11Lymphoma, Follicular 11Glioblastoma 11Tuberous Sclerosis 10Lymphoma, B-Cell, Marginal Zone 10Carcinoma, Renal Cell 10Neoplasms 9Hematologic Neoplasms 9Gliosarcoma 9Carcinoma, Hepatocellular 9Breast Neoplasms 9Brain Neoplasms 9Waldenstrom Macroglobulinemia 8Myeloproliferative Disorders 8Melanoma 8Burkitt Lymphoma 8Recurrence 7Neoplasm Metastasis 7

Interventions

Vincristine 3Topotecan 3Stem Cell Transplantation 3Radiation 3Platinum 3Melphalan 3Doxorubicin 3Cyclophosphamide 3Congresses as Topic 3Cisplatin 31,2-diaminocyclohexaneplatinum II citrate 3sargramostim 2dinutuximab 2Isotretinoin 2Etoposide 2Colony-Stimulating Factors 2Busulfan 2temsirolimus 1etoposide phosphate 1Thiotepa 1Temozolomide 1Sirolimus 1Razoxane 1Radiotherapy, Intensity-Modulated 1Radiotherapy, Conformal 1Peripheral Blood Stem Cell Transplantation 1Mesna 1Irinotecan 1Granulocyte Colony-Stimulating Factor 1Filgrastim 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Ganglioneuroblastoma × Sirolimus × Clear all
NCT01767194 2022-10-24

Irinotecan Hydrochloride and Temozolomide With Temsirolimus or Dinutuximab in Treating Younger Patients With Refractory or Relapsed Neuroblastoma

National Cancer Institute (NCI)

Phase 2 Completed
73 enrolled 12 charts
CNS

Neuroblastoma, Ganglioneuroblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡